High-grade Clear Cell Renal Cell Carcinoma Has a Higher Angiogenic Activity Than Low-grade Renal Cell Carcinoma Based on Histomorphological Quantification and QRT-PCR MRNA Expression Profile
Overview
Authors
Affiliations
Clear cell renal cell carcinoma (CC-RCC) is a highly vascularised tumour and is therefore an attractive disease to study angiogenesis and to test novel angiogenesis inhibitors in early clinical development. Endothelial cell proliferation plays a pivotal role in the process of angiogenesis. The aim of this study was to compare angiogenesis parameters in low nuclear grade (n=87) vs high nuclear grade CC-RCC (n=63). A panel of antibodies was used for immunohistochemistry: CD34/Ki-67, carbonic anhydrase IX, hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF). Vessel density (MVD - microvessel density), endothelial cell proliferation fraction (ECP%) and tumour cell proliferation fraction (TCP%) were assessed. mRNA expression levels of angiogenesis stimulators and inhibitors were determined by quantitative RT-PCR. High-grade CC-RCC showed a higher ECP% (P=0.049), a higher TCP% (P=0.009), a higher VEGF protein expression (P<0.001), a lower MVD (P< 0.001) and a lower HIF-1alpha protein expression (P=0.002) than low-grade CC-RCC. Growth factor mRNA expression analyses revealed a higher expression of angiopoietin 2 in low-grade CC-RCC. Microvessel density and ECP% were inversely correlated (Rho=-0.26, P=0.001). Because of the imperfect association of nuclear grade and ECP% or MVD, CC-RCC was also grouped based on low/high MVD and ECP%. This analysis revealed a higher expression of vessel maturation and stabilisation factors (placental growth factor, PDGFB1, angiopoietin 1) in CC-RCC with high MVD, a group of CC-RCC highly enriched in low nuclear grade CC-RCC, with low ECP%. Our results suggest heterogeneity in angiogenic activity and vessel maturation of CC-RCC, to a large extent linked to nuclear grade, and, with probable therapeutic implications.
Hypoxia-inducible factor in breast cancer: role and target for breast cancer treatment.
Zhi S, Chen C, Huang H, Zhang Z, Zeng F, Zhang S Front Immunol. 2024; 15:1370800.
PMID: 38799423 PMC: 11116789. DOI: 10.3389/fimmu.2024.1370800.
Mohammadipoor N, Naiebi R, Mazhari S, Amooei F, Owrang M, Dastghaib S Mol Biol Rep. 2024; 51(1):379.
PMID: 38429605 DOI: 10.1007/s11033-024-09355-2.
Mazumder S, Higgins P, Samarakoon R Cancers (Basel). 2023; 15(4).
PMID: 36831657 PMC: 9953937. DOI: 10.3390/cancers15041316.
Zekan D, Wasef K, Werner Z, Grammer R, Lombard C, Luchey A Case Rep Urol. 2022; 2022:9176199.
PMID: 36439648 PMC: 9691311. DOI: 10.1155/2022/9176199.
Drljevic-Nielsen A, Rasmussen F, Nielsen P, Stilling C, Thorup K, Mains J Eur Radiol Exp. 2021; 5(1):32.
PMID: 34327591 PMC: 8322257. DOI: 10.1186/s41747-021-00232-2.